HIV IMMUNITY AND ERADICATION, A HERRENHAUSEN SYMPOSIUM November 2-3, 2017 | Hanover, Germany REGISTER NOW! | | | | | | Letter to the Editor | Top | | The CYP2D6 VCF TranslatorW Qiao, J Wang, B S Pullman, R Chen, Y Yang and S A Scott Pharmacogenomics J 2017 17: 301-303; advance online publication, March 15, 2016; 10.1038/tpj.2016.14 Full Text | | Review | Top | | More than 25 years of genetic studies of clozapine-induced agranulocytosisS A J de With, S L Pulit, W G Staal, R S Kahn and R A Ophoff Pharmacogenomics J 2017 17: 304-311; advance online publication, April 18, 2017; 10.1038/tpj.2017.6 Abstract | Full Text | | Original Articles | Top | | Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association studyS Mahurkar, M Moldovan, V Suppiah, M Sorosina, F Clarelli, G Liberatore, S Malhotra, X Montalban, A Antigüedad, M Krupa, V G Jokubaitis, F C McKay, P N Gatt, M J Fabis-Pedrini, V Martinelli, G Comi, J Lechner-Scott, A G Kermode, M Slee, B V Taylor, K Vandenbroeck, M Comabella, F M Boneschi, The Australian and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene) and C King Pharmacogenomics J 2017 17: 312-318; advance online publication, March 22, 2016; 10.1038/tpj.2016.20 Abstract | Full Text | | | | The impact of ABCC11 polymorphisms on the risk of early-onset fluoropyrimidine toxicityS Hamzic, N Wenger, T K Froehlich, M Joerger, S Aebi, C R Largiadèr and U Amstutz Pharmacogenomics J 2017 17: 319-324; advance online publication, March 22, 2016; 10.1038/tpj.2016.23 Abstract | Full Text | | | | Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): a pharmacogenomic study of metabolic enzymes and transportersY Ma, S Xin, M Huang, Y Yang, C Zhu, H Zhao, Y Zhang, L Chen, Y Zhao, J Li, W Zhuang, X Zhu, L Zhang and X Wang Pharmacogenomics J 2017 17: 325-330; advance online publication, April 19, 2016; 10.1038/tpj.2016.31 Abstract | Full Text | | | | Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumabF S Falvella, C Cremolini, R Miceli, F Nichetti, S Cheli, C Antoniotti, G Infante, A Martinetti, F Marmorino, E Sottotetti, R Berenato, M Caporale, A Colombo, F de Braud, M Di Bartolomeo, E Clementi, F Loupakis and F Pietrantonio Pharmacogenomics J 2017 17: 331-336; advance online publication, March 22, 2016; 10.1038/tpj.2016.22 Abstract | Full Text | | | | Pharmacogenetics of ABCB5, ABCC5 and RLIP76 and doxorubicin pharmacokinetics in Asian breast cancer patientsS Lal, N Sutiman, L L Ooi, Z W Wong, N S Wong, P C S Ang and B Chowbay Pharmacogenomics J 2017 17: 337-343; advance online publication, March 15, 2016; 10.1038/tpj.2016.17 Abstract | Full Text | | | | Endothelin-1 genetic polymorphism as predictive marker for bevacizumab in metastatic breast cancerS P Gampenrieder, C Hufnagl, S Brechelmacher, F Huemer, H Hackl, G Rinnerthaler, F Romeder, C Monzo Fuentes, P Morre, C Hauser-Kronberger, B Mlineritsch and R Greil Pharmacogenomics J 2017 17: 344-350; advance online publication, May 3, 2016; 10.1038/tpj.2016.25 Abstract | Full Text | | | | Integrated Drug Expression Analysis for leukemia: an integrated in silico and in vivo approach to drug discoveryM H Ung, C-H Sun, C-W Weng, C-C Huang, C-C Lin, C-C Liu and C Cheng Pharmacogenomics J 2017 17: 351-359; advance online publication, March 15, 2016; 10.1038/tpj.2016.18 Abstract | Full Text | | | | KIR2DS2 as predictor of thrombocytopenia secondary to pegylated interferon-alpha therapyA Rivero-Juarez, R Gonzalez, M Frias, B Manzanares-Martín, D Rodriguez-Cano, I Perez-Camacho, A Gordon, F Cuenca, A Camacho, J A Pineda, J Peña and A Rivero Pharmacogenomics J 2017 17: 360-365; advance online publication, March 15, 2016; 10.1038/tpj.2016.19 Abstract | Full Text | | | | Genetic variation in the alpha1B-adrenergic receptor and vascular responseA Adefurin, L V Ghimire, U Kohli, M Muszkat, G G Sofowora, C Li, R T Levinson, S Y Paranjape, C M Stein and D Kurnik Pharmacogenomics J 2017 17: 366-371; advance online publication, April 19, 2016; 10.1038/tpj.2016.29 Abstract | Full Text | | | | Risk factors of isoniazid-induced hepatotoxicity in Tunisian tuberculosis patientsN Ben Fredj, R Gam, E Kerkni, A Chaabane, Z Chadly, N Boughattas and K Aouam Pharmacogenomics J 2017 17: 372-377; advance online publication, April 19, 2016; 10.1038/tpj.2016.26 Abstract | Full Text | | | | High frequency of CYP2D6 ultrarapid metabolizer genotypes in an Ashkenazi Jewish population from ArgentinaG Moya, P Dorado, V Ferreiro, M E G Naranjo, E M Peñas-Lledó and A LLerena Pharmacogenomics J 2017 17: 378-381; advance online publication, April 12, 2016; 10.1038/tpj.2016.27 Abstract | Full Text | | | | Prevalence and implications of cytochrome P450 substrates in Massachusetts hospital dischargesT H McCoy, V M Castro, A Cagan, A M Roberson and R H Perlis Pharmacogenomics J 2017 17: 382-385; advance online publication, May 10, 2016; 10.1038/tpj.2016.24 Abstract | Full Text | | | | Assessment of pharmacogenetic tests: presenting measures of clinical validity and potential population impact in association studies OPENE C M Tonk, D Gurwitz, A-H Maitland-van der Zee and A C J W Janssens Pharmacogenomics J 2017 17: 386-392; advance online publication, May 10, 2016; 10.1038/tpj.2016.34 Abstract | Full Text | | Erratum | Top | | Pharmacogenetic comparison of CYP2D6 predictive and measured phenotypes in a South African cohortT M Dodgen, C De J Labuschagne, A van Schalkwyk, F E Steffens, A Gaedigk, A D Cromarty, M Alessandrini and M S Pepper Pharmacogenomics J 2017 17: 393; 10.1038/tpj.2017.20 Full Text | | | | Advertisement | | MEDTECH DEALMAKERS A supplement to Nature Biotechnology | Nature Medicine | Nature Reviews Drug Discovery Medtech Dealmakers explores the dealmaking strategies of the growing medical technology industry, and provides in-depth analysis of emerging technologies, as well as showcase innovative companies seeking partners. Check out the latest issue for medtech dealmaking and financing trends in 2016, and diagnostics deals from the past year- particularly for immuno oncology applications. Download the issue for FREE | | | | | | | | | | | | Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.
Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com | | | | | | | | Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to The Pharmacogenomics Journal. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Springer Nature |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Springer Nature's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2017 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved. | | | |
1 comment:
I’m really amazed with your posting skills as well as with the layout on your blog site. Very informative and well written post! Quite interesting and nice topic chosen for the post Nice Post keep it up.Excellent post.
pharmacogenetics testing
Post a Comment